260 related articles for article (PubMed ID: 21767644)
21. Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders.
Mundiñano IC; Caballero MC; Ordóñez C; Hernandez M; DiCaudo C; Marcilla I; Erro ME; Tuñon MT; Luquin MR
Acta Neuropathol; 2011 Jul; 122(1):61-74. PubMed ID: 21553300
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
23. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
Piltonen M; Savolainen M; Patrikainen S; Baekelandt V; Myöhänen TT; Männistö PT
Neuroscience; 2013 Feb; 231():157-68. PubMed ID: 23219665
[TBL] [Abstract][Full Text] [Related]
24. Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein.
Chadchankar H; Ihalainen J; Tanila H; Yavich L
Brain Res; 2011 Mar; 1382():37-44. PubMed ID: 21276428
[TBL] [Abstract][Full Text] [Related]
25. Inducible dopaminergic glutathione depletion in an α-synuclein transgenic mouse model results in age-related olfactory dysfunction.
Kim YH; Lussier S; Rane A; Choi SW; Andersen JK
Neuroscience; 2011 Jan; 172():379-86. PubMed ID: 21055449
[TBL] [Abstract][Full Text] [Related]
26. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
27. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
[TBL] [Abstract][Full Text] [Related]
28. α-Synuclein Pathology and Reduced Neurogenesis in the Olfactory System Affect Olfaction in a Mouse Model of Parkinson's Disease.
Martin-Lopez E; Vidyadhara DJ; Liberia T; Meller SJ; Harmon LE; Hsu RM; Spence N; Brennan B; Han K; Yücel B; Chandra SS; Greer CA
J Neurosci; 2023 Feb; 43(6):1051-1071. PubMed ID: 36596700
[TBL] [Abstract][Full Text] [Related]
29. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein.
Zhang S; Xiao Q; Le W
PLoS One; 2015; 10(3):e0119928. PubMed ID: 25799501
[TBL] [Abstract][Full Text] [Related]
30. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
31. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice.
Plaas M; Karis A; Innos J; Rebane E; Baekelandt V; Vaarmann A; Luuk H; Vasar E; Koks S
J Physiol Pharmacol; 2008 Jun; 59(2):205-16. PubMed ID: 18622040
[TBL] [Abstract][Full Text] [Related]
32. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
33. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
34. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1.
Lin X; Parisiadou L; Sgobio C; Liu G; Yu J; Sun L; Shim H; Gu XL; Luo J; Long CX; Ding J; Mateo Y; Sullivan PH; Wu LG; Goldstein DS; Lovinger D; Cai H
J Neurosci; 2012 Jul; 32(27):9248-64. PubMed ID: 22764233
[TBL] [Abstract][Full Text] [Related]
35. Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61") transgenic mouse line.
Delenclos M; Carrascal L; Jensen K; Romero-Ramos M
Neuroscience; 2014 Sep; 277():647-64. PubMed ID: 25090921
[TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
Martin LJ; Pan Y; Price AC; Sterling W; Copeland NG; Jenkins NA; Price DL; Lee MK
J Neurosci; 2006 Jan; 26(1):41-50. PubMed ID: 16399671
[TBL] [Abstract][Full Text] [Related]
37. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
38. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M
Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotection of α-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K.
Choong CJ; Say YH
Neurotoxicology; 2011 Dec; 32(6):857-63. PubMed ID: 21658409
[TBL] [Abstract][Full Text] [Related]
40. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
